Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
24.85 x 1 34.00 x 1
Post-market by (Cboe BZX)
27.66 +0.52 (+1.92%) 04/17/25 [NASDAQ]
24.85 x 1 34.00 x 1
Post-market 27.66 unch (unch) 16:32 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
26.99
Day High
28.38
Open 27.11
Previous Close 27.14 27.14
Volume 590,600 590,600
Avg Vol 745,020 745,020
Stochastic %K 58.54% 58.54%
Weighted Alpha -17.64 -17.64
5-Day Change +2.35 (+9.28%) +2.35 (+9.28%)
52-Week Range 23.42 - 62.58 23.42 - 62.58
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,584,807
  • Shares Outstanding, K 57,296
  • Annual Sales, $ 36,500 K
  • Annual Income, $ 673,730 K
  • EBIT $ -426 M
  • EBITDA $ -435 M
  • 60-Month Beta 0.83
  • Price/Sales 42.61
  • Price/Cash Flow N/A
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 74.23% ( -9.69%)
  • Historical Volatility 56.42%
  • IV Percentile 96%
  • IV Rank 76.03%
  • IV High 91.49% on 04/08/25
  • IV Low 19.51% on 05/16/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 94
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 8,457
  • Open Int (30-Day) 8,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.80
  • Number of Estimates 5
  • High Estimate -1.53
  • Low Estimate -2.01
  • Prior Year -1.45
  • Growth Rate Est. (year over year) -24.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.42 +18.10%
on 04/09/25
Period Open: 31.99
32.90 -15.93%
on 03/21/25
-4.33 (-13.54%)
since 03/17/25
3-Month
23.42 +18.10%
on 04/09/25
Period Open: 32.42
36.17 -23.53%
on 02/24/25
-4.76 (-14.68%)
since 01/17/25
52-Week
23.42 +18.10%
on 04/09/25
Period Open: 29.03
62.58 -55.80%
on 11/11/24
-1.37 (-4.72%)
since 04/17/24

Most Recent Stories

More News
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

AGIO : 27.66 (+1.92%)
New Strong Sell Stocks for April 8th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Air France-KLM AFLYY is an airline company with core business is passenger transport, cargo transport, and aircraft maintenance...

AGIO : 27.66 (+1.92%)
AFLYY : 0.8208 (+1.27%)
ARLP : 27.17 (+1.44%)
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

AGIO : 27.66 (+1.92%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 27.66 (+1.92%)
CLDX : 18.30 (+2.81%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 27.66 (+1.92%)
CLDX : 18.30 (+2.81%)
Agios to Present at Upcoming Investor Conferences

AGIO : 27.66 (+1.92%)
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

AGIO : 27.66 (+1.92%)
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals AGIO incurred a loss of $1.74 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.73. In the year-ago quarter, the company had reported...

AGIO : 27.66 (+1.92%)
HRMY : 28.46 (+1.86%)
PCRX : 24.65 (+0.74%)
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

AGIO : 27.66 (+1.92%)
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

AGIO : 27.66 (+1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 29.75
2nd Resistance Point 29.07
1st Resistance Point 28.36
Last Price 27.66
1st Support Level 26.97
2nd Support Level 26.28
3rd Support Level 25.58

See More

52-Week High 62.58
Fibonacci 61.8% 47.62
Fibonacci 50% 43.00
Fibonacci 38.2% 38.38
Last Price 27.66
52-Week Low 23.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro